Literature DB >> 26646038

Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.

Frederik Vandenberghe1, Mehdi Gholam-Rezaee, Núria Saigí-Morgui, Aurélie Delacrétaz, Eva Choong, Alessandra Solida-Tozzi, Stéphane Kolly, Jacques Thonney, Sylfa Fassassi Gallo, Ahmed Hedjal, Anne-Emmanuelle Ambresin, Armin von Gunten, Philippe Conus, Chin B Eap.   

Abstract

BACKGROUND: Psychotropic drugs can induce substantial weight gain, particularly during the first 6 months of treatment. The authors aimed to determine the potential predictive power of an early weight gain after the introduction of weight gain-inducing psychotropic drugs on long-term weight gain.
METHOD: Data were obtained from a 1-year longitudinal study ongoing since 2007 including 351 psychiatric (ICD-10) patients, with metabolic parameters monitored (baseline and/or 1, 3, 6, 9, 12 months) and with compliance ascertained. International Diabetes Federation and World Health Organization definitions were used to define metabolic syndrome and obesity, respectively.
RESULTS: Prevalences of metabolic syndrome and obesity were 22% and 17%, respectively, at baseline and 32% and 24% after 1 year. Receiver operating characteristic analyses indicated that an early weight gain > 5% after a period of 1 month is the best predictor for important long-term weight gain (≥ 15% after 3 months: sensitivity, 67%; specificity, 88%; ≥ 20% after 12 months: sensitivity, 47%; specificity, 89%). This analysis identified most patients (97% for 3 months, 93% for 12 months) who had weight gain ≤ 5% after 1 month as continuing to have a moderate weight gain after 3 and 12 months. Its predictive power was confirmed by fitting a longitudinal multivariate model (difference between groups in 1 year of 6.4% weight increase as compared to baseline, P = .0001).
CONCLUSION: Following prescription of weight gain-inducing psychotropic drugs, a 5% threshold for weight gain after 1 month should raise clinician concerns about weight-controlling strategies. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26646038     DOI: 10.4088/JCP.14m09358

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

1.  Psychotherapy Alone and Combined With Medication as Treatments for Bipolar II Depression: A Randomized Controlled Trial.

Authors:  Holly A Swartz; Paola Rucci; Michael E Thase; Meredith Wallace; Elisa Carretta; Karen L Celedonia; Ellen Frank
Journal:  J Clin Psychiatry       Date:  2018 Mar/Apr       Impact factor: 4.384

Review 2.  Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.

Authors:  Ann A Verhaegen; Luc F Van Gaal
Journal:  Curr Obes Rep       Date:  2021-01-05

Review 3.  Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.

Authors:  A A Verhaegen; L F Van Gaal
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

4.  Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study.

Authors:  Jess G Fiedorowicz; Lisa Brown; James Li; Sagar V Parikh; Boadie W Dunlop; Brent P Forester; Richard C Shelton; Michael E Thase; Matthew Macaluso; Kunbo Yu; John F Greden
Journal:  Psychopharmacol Bull       Date:  2021-11-03

Review 5.  Cardiometabolic effects of psychotropic medications.

Authors:  Oluchi Abosi; Sneha Lopes; Samantha Schmitz; Jess G Fiedorowicz
Journal:  Horm Mol Biol Clin Investig       Date:  2018-01-10

6.  Risperidone-Induced Adverse Drug Reactions and Role of DRD2 (-141 C Ins/Del) and 5HTR2C (-759 C>T) Genetic Polymorphisms in Patients with Schizophrenia.

Authors:  Charanraj Goud Alladi; Anbarasan Mohan; Deepak Gopal Shewade; Ravi Philip Rajkumar; Surendiran Adithan; Karthick Subramanian
Journal:  J Pharmacol Pharmacother       Date:  2017 Jan-Mar

7.  A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia.

Authors:  Anabel Perez-Gomez; Maria Carretero; Natalie Weber; Veronika Peterka; Alan To; Viktoriya Titova; Gregory Solis; Olivia Osborn; Michael Petrascheck
Journal:  Nat Commun       Date:  2018-12-10       Impact factor: 14.919

8.  Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances.

Authors:  Aurélie Delacrétaz; Frederik Vandenberghe; Anaïs Glatard; Axel Levier; Céline Dubath; Nicolas Ansermot; Séverine Crettol; Mehdi Gholam-Rezaee; Idris Guessous; Murielle Bochud; Armin von Gunten; Philippe Conus; Chin B Eap
Journal:  Front Psychiatry       Date:  2018-11-09       Impact factor: 4.157

Review 9.  Antipsychotic-associated weight gain: management strategies and impact on treatment adherence.

Authors:  Madhubhashinee Dayabandara; Raveen Hanwella; Suhashini Ratnatunga; Sudarshi Seneviratne; Chathurie Suraweera; Varuni A de Silva
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-22       Impact factor: 2.570

Review 10.  Is It Possible to Predict the Future in First-Episode Psychosis?

Authors:  Jaana Suvisaari; Outi Mantere; Jaakko Keinänen; Teemu Mäntylä; Eva Rikandi; Maija Lindgren; Tuula Kieseppä; Tuukka T Raij
Journal:  Front Psychiatry       Date:  2018-11-13       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.